Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by various company officials on July 5, 2012. These acquisitions occurred at a price of 1,481.088 pence per share and resulted from the reinvestment of dividends paid on shares held in the GlaxoSmithKline ShareReward Plan. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Insider share acquisitions via dividend reinvestment.
- Transaction Date: July 5, 2012.
- Share Price: 1,481.088 pence per Ordinary Share.
- Participants: Includes Sir Andrew Witty (22 shares), Mr S M Bicknell (35 shares), Mr S Dingemans (3 shares), Mr E J Gray (35 shares), Mr S A Hussain (7 shares), Dr D Pulman (11 shares), Mr D S Redfern (35 shares), Ms C Thomas (35 shares), Mr P C Thomson (14 shares), Dr P J T Vallance (17 shares), and Mrs V A Whyte (22 shares).
- Source of Funds: Reinvestment of dividends from the GlaxoSmithKline ShareReward Plan.